The advantages of early application of infliximab to Crohn's disease treatment
- Author:
Pin HUANG
1
Author Information
1. Gastroenterology
- Publication Type:Journal Article
- Keywords:
Azathioprine;
Crohn's disease;
Infliximab
- From:
Chinese Pharmaceutical Journal
2012;47(8):642-644
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To investigate the clinical efficacy of early application of infliximab to Crohn's disease treatment. METHODS: Forty-eight patients with Crohn's disease were randomly divided into ATI group and AZA group with 24 patients in each group. The patients in ATI group were treated with infliximab in the first 14 weeks while the patients in AZA group only used azathioprine. Both groups were followed up for 50 weeks. The clinical efficacy, adverse reactions, treatment effective time and recurrences were compared between the two groups. RESULTS: The clinical effective rate in the ATI group was 91.67%, significantly higher than that in AZA group (66.67%, P<0.05); the average time of cure for the ATI group was shorter than the control group (P<0.05); the mucosal healing rates was 25.00%, significantly higher than the AZA group (4.17%, P<0.05); the recurrence rate in the ATI group was 16.66%, lower than the AZA group (37.50%, P<0.05). CONCLUSION: The method has good efficacy for Crohn's disease. It can significantly improve the clinical efficacy, reduce adverse reactions, complications and recurrence rate, and should be widely used in clinic. Copyright 2012 by the Chinese Pharmaceutical Association.
